{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:12:53Z","timestamp":1792037573182,"version":"4.4.0"},"reference-count":218,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Since November 2019 the SARS-CoV-2 pandemic has caused nearly 200 million infection and more than 4 million deaths globally (Updated information from the World Health Organization, as on 2<jats:sup>nd<\/jats:sup>Aug 2021). Within only one year into the pandemic, several vaccines were designed and reached approval for the immunization of the world population. The remarkable protective effects of the manufactured vaccines are demonstrated in countries with high vaccination rates, such as Israel and UK. However, limited production capacities, poor distribution infrastructures and political hesitations still hamper the availability of vaccines in many countries. In addition, due to the emergency of SARS-CoV-2 variants with immune escape properties towards the vaccines the global numbers of new infections as well as patients developing severe COVID-19, remains high. New studies reported that about 8% of infected individuals develop long term symptoms with strong personal restrictions on private as well as professional level, which contributes to the long socioeconomic problems caused by this pandemic. Until today, emergency use-approved treatment options for COVID-19 are limited to the antiviral Remdesivir, a nucleoside analogue targeting the viral polymerase, the glucocorticosteroide Dexamethasone as well as neutralizing antibodies. The therapeutic benefits of these treatments are under ongoing debate and clinical studies assessing the efficiency of these treatments are still underway. To identify new therapeutic treatments for COVID-19, now and by the post-pandemic era, diverse experimental approaches are under scientific evaluation in companies and scientific research teams all over the world. To accelerate clinical translation of promising candidates, repurposing approaches of known approved drugs are specifically fostered but also novel technologies are being developed and are under investigation. This review summarizes the recent developments from the lab bench as well as the clinical status of emerging therapeutic candidates and discusses possible therapeutic entry points for the treatment strategies with regard to the biology of SARS-CoV-2 and the clinical course of COVID-19.<\/jats:p>","DOI":"10.3389\/fimmu.2021.752227","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T18:19:19Z","timestamp":1633112359000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics"],"prefix":"10.3389","volume":"12","author":[{"given":"Sriram","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duygu Merve","family":"\u00c7al\u0131\u015fkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josua","family":"Janowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Faist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate Claudine Gisela","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Brunotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease-2019 (COVID-19): The Epidemic and the Challenges","volume":"55","author":"Lai","year":"2020","journal-title":"Int J Antimicrobial Agents"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic Characterisation and Epidemiology of 2019 Novel Coronavirus: Implications for Virus Origins and Receptor Binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041797","article-title":"Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes Sars-Cov-2 Infection and Progress to Covid-19","volume":"22","author":"Blaess","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkg916","article-title":"Molecular Model of SARS Coronavirus Polymerase: Implications for Biochemical Functions and Drug Design","volume":"31","author":"Xu","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/JCMA.0000000000000319","article-title":"Gastrointestinal and Liver Manifestations in Patients With COVID-19","volume":"83","author":"Lee","year":"2020","journal-title":"J Chin Med Assoc"},{"key":"B9","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10238-020-00648-x","article-title":"Organ-Specific Manifestations of COVID-19 Infection","volume":"20","author":"Gavriatopoulou","year":"2020","journal-title":"Clin Exp Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"m1091","DOI":"10.1136\/bmj.m1091","article-title":"Clinical Characteristics of 113 Deceased Patients With Coronavirus Disease 2019: Retrospective Study","volume":"368","author":"Chen","year":"2020","journal-title":"BMJ"},{"key":"B11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical Features of Patients Infected With 2019 Novel Coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40779-020-00240-0","article-title":"The Origin, Transmission and Clinical Therapies on Coronavirus Disease 2019 (COVID-19) Outbreak- A N Update on the Status","volume":"7","author":"Guo","year":"2020","journal-title":"Military Med Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.570993","article-title":"Controlling Cytokine Storm Is Vital in COVID-19","volume":"11","author":"Tang","year":"2020","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2020.03.012","article-title":"COVID-19 Illness in Native and Immunosuppressed States: A Clinical\u2013Therapeutic Staging Proposal","volume":"39","author":"Siddiqi","year":"2020","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/path.1570","article-title":"Tissue Distribution of ACE2 Protein, the Functional Receptor for SARS Coronavirus. A First Step in Understanding SARS Pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102976","article-title":"Heterogeneous Expression of the SARS-Coronavirus-2 Receptor ACE2 in the Human Respiratory Tract","volume":"60","author":"Ortiz","year":"2020","journal-title":"EBioMedicine"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2020.101205","article-title":"Aging in COVID-19: Vulnerability, Immunity and Intervention","volume":"65","author":"Chen","year":"2021","journal-title":"Ageing Res Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA - J Am Med Assoc"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2020.0289","article-title":"COVID-19 in Cancer Patients: Risk, Clinical Features, and Management","volume":"17","author":"Liu","year":"2020","journal-title":"Cancer Biol Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.004","article-title":"Clinical Progression of Patients With COVID-19 in Shanghai, China","volume":"80","author":"Chen","year":"2020","journal-title":"J Infect"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-020-05698-w","article-title":"Effect of Arbidol (Umifenovir) on COVID-19: A Randomized Controlled Trial","volume":"20","author":"Nojomi","year":"2020","journal-title":"BMC Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105998","article-title":"Arbidol: A Potential Antiviral Drug for the Treatment of SARS-CoV-2 by Blocking Trimerization of the Spike Glycoprotein","volume":"56","author":"Vankadari","year":"2020","journal-title":"Int J Antimicrobial Agents"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173836","article-title":"Unraveling the Mechanism of Arbidol Binding and Inhibition of SARS-CoV-2: Insights From Atomistic Simulations","volume":"894","author":"Padhi","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.04.026","article-title":"Umifenovir Treatment is Not Associated With Improved Outcomes in Patients With Coronavirus Disease 2019: A Retrospective Study","volume":"26","author":"Lian","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.002","article-title":"Arbidol Combined With LPV\/r Versus LPV\/r Alone Against Corona Virus Disease 2019: A Retrospective Cohort Study","volume":"81","author":"Deng","year":"2020","journal-title":"J Infect"},{"key":"B26","doi-asserted-by":"publisher","first-page":"11871195","DOI":"10.1016\/j.jiph.2020.07.013","article-title":"Clinical Efficacy of Antivirals Against Novel Coronavirus (COVID-19): A Review","volume":"13","author":"Jomah","year":"2020","journal-title":"J Infect Public Health"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26256","article-title":"Efficacy and Safety of Umifenovir for Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis","volume":"93","author":"Huang","year":"2021","journal-title":"J Med Virol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-86169\/v1","article-title":"Clofazimine is a Broad-Spectrum Coronavirus Inhibitor That Antagonizes SARS-CoV-2 Replication in Primary Human Cell Culture and Hamsters","author":"Yuan","year":"2020","journal-title":"Res Square"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2007408117","article-title":"Effectiveness of Convalescent Plasma Therapy in Severe COVID-19 Patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA - J Am Med Assoc"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.3346\/jkms.2020.35.e149","article-title":"Use of Convalescent Plasma Therapy in Two Covid-19 Patients With Acute Respiratory Distress Syndrome in Korea","volume":"35","author":"Ahn","year":"2020","journal-title":"J Korean Med Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2020.05.014","article-title":"Treatment of Coronavirus Disease 2019 (COVID-19) Patients With Convalescent Plasma","volume":"190","author":"Salazar","year":"2020","journal-title":"Am J Pathol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12607","article-title":"Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-Threatening COVID-19: A Randomized Clinical Trial","volume":"324","author":"Li","year":"2020","journal-title":"JAMA - J Am Med Assoc"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01064-3","article-title":"Convalescent Plasma in Patients Hospitalised With COVID-19","volume":"397","author":"Liu","year":"2021","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138003","article-title":"The Convalescent Sera Option for Containing COVID-19","volume":"130","author":"Casadevall","year":"2020","journal-title":"J Clin Invest"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03291-y","article-title":"SARS-CoV-2 Evolution During Treatment of Chronic Infection","volume":"592","author":"Kemp","year":"2021","journal-title":"Nature"},{"key":"B37","volume-title":"Drugs and Lactation Database","year":"2021"},{"key":"B38","volume-title":"Drugs and Lactation Database","year":"2021"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA - J Am Med Assoc"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0831","article-title":"Antibody Cocktail to SARS-CoV-2 Spike Protein Prevents Rapid Mutational Escape Seen With Individual Antibodies","volume":"369","author":"Baum","year":"2020","journal-title":"Science"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients With Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.09.434607","article-title":"The Dual Function Monoclonal Antibodies VIR-7831 and VIR-7832 Demonstrate Potent In Vitro and 2 In Vivo Activity Against SARS-CoV-2 3 4 5","author":"Cathcart","year":"2021","journal-title":"bioRxiv"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1016\/S2213-2600(20)30418-5","article-title":"Human Recombinant Soluble ACE2 in Severe COVID-19","volume":"8","author":"Zoufaly","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-0430-6","article-title":"Recombinant Human ACE2: Potential Therapeutics of SARS-CoV-2 Infection and Its Complication","volume":"41","author":"Pang","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e13426","DOI":"10.15252\/emmm.202013426","article-title":"Human Soluble ACE2 Improves the Effect of Remdesivir in SARS-CoV-2 Infection","volume":"13","author":"Monteil","year":"2021","journal-title":"EMBO Mol Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"eabb5676","DOI":"10.1126\/scitranslmed.abb5676","article-title":"An ACE Therapy for COVID-19","volume":"12","author":"Rodell","year":"2020","journal-title":"Sci Trans Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.22211.1","article-title":"Therapeutic Strategies in an Outbreak Scenario to Treat the Novel Coronavirus Originating in Wuhan, China","volume":"9","author":"Kruse","year":"2020","journal-title":"F1000Research"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1101\/2020.12.06.413443","article-title":"Efficient Inhibition of SARS-CoV-2 Strains by a Novel ACE2-IgG4-Fc Fusion Protein With a Stabilized Hinge Region","author":"Svilenov","year":"2020","journal-title":"bioRxiv"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/j.cegh.2020.07.011","article-title":"Remdesivir and Its Antiviral Activity Against COVID-19: A Systematic Review","volume":"9","author":"Frediansyah","year":"2021","journal-title":"Clin Epidemiol Global Health"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and Therapeutic Remdesivir (GS-5734) Treatment in the Rhesus Macaque Model of MERS-CoV Infection","volume":"117","author":"de Wit","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001191","article-title":"First Case of 2019 Novel Coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"New Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/JEP.S255209","article-title":"Experimental Pharmacotherapy for Covid-19: The Latest Advances","volume":"13","author":"Pagliano","year":"2021","journal-title":"J Exp Pharmacol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2022236","article-title":"Remdesivir for the Treatment of Covid-19 \u2014 Final Report","volume":"383","author":"Beigel","year":"2020","journal-title":"New Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"100733","DOI":"10.1016\/j.drup.2020.100733","article-title":"COVID-19 Update: The Race to Therapeutic Development","volume":"53","author":"Twomey","year":"2020","journal-title":"Drug Resistance Updates"},{"key":"B55","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed Antiviral Drugs for COVID-19 \u2013Interim WHO SOLIDARITY Trial Results","volume":"348","author":"Pan","year":"2020","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30911-7","article-title":"The Place for Remdesivir in COVID-19 Treatment","volume":"21","author":"Young","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.mjafi.2020.08.004","article-title":"Favipiravir: A New and Emerging Antiviral Option in COVID-19","volume":"76","author":"Agrawal","year":"2020","journal-title":"Med J Armed Forces India"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1124\/mol.113.087247","article-title":"Role of Human Hypoxanthine Guanine Phosphoribosyltransferase in Activation of the Antiviral Agent T-705 (Favipiravir)","volume":"84","author":"Naesens","year":"2013","journal-title":"Mol Pharmacol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.10.069","article-title":"Role of Favipiravir in the Treatment of COVID-19","volume":"102","author":"Joshi","year":"2021","journal-title":"Int J Infect Dis"},{"key":"B60","doi-asserted-by":"publisher","first-page":"7","DOI":"10.29121\/granthaalayah.v8.i4.2020.2","article-title":"Favipiravir as a Potential Drug in the Treatment of COVID-19","volume":"8","author":"Kramer","year":"2020","journal-title":"Int J Res - GRANTHAALAYAH"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s42399-021-00824-4","article-title":"Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: A Comprehensive Clinical and Pharmacovigilant Reassessment","volume":"3","author":"Kelleni","year":"2021","journal-title":"SN Compr Clin Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2055-6640(20)30016-9","article-title":"A Review of the Safety of Favipiravir \u2013 a Potential Treatment in the COVID-19 Pandemic","volume":"6","author":"Pilkington","year":"2020","journal-title":"J Virus Eradication"},{"key":"B63","doi-asserted-by":"publisher","first-page":"683296","DOI":"10.1101\/2020.03.17.20037432","article-title":"Favipiravir Versus Arbidol for COVID-19: A Randomized Clinical Trial","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental Treatment With Favipiravir for COVID-19: An Open-Label Control Study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-021-04956-9","article-title":"Efficacy of Favipiravir in COVID-19 Treatment: A Multi-Center Randomized Study","volume":"166","author":"Dabbous","year":"2021","journal-title":"Arch Virol"},{"key":"B66","volume-title":"Favipiravir to be Investigated as a Possible COVID-19 Treatment for at-Home Recovery in the PRINCIPLE Trial \u2014 PRINCIPLE Trial","year":"2021"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02428-20","article-title":"Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent With Activity Against SARS-CoV-2","volume":"65","author":"Painter","year":"2021","journal-title":"Antimicrobial Agents Chemother"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1101\/2020.12.10.419242","article-title":"The Combined Treatment of Molnupiravir and Favipiravir Results in a Marked Potentiation of Antiviral Efficacy in a SARS-CoV-2 Hamster Infection Model","author":"Abdelnabi","year":"2021","journal-title":"bioRxiv"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110668","article-title":"Insights Into Antiviral Mechanisms of Remdesivir, Lopinavir\/Ritonavir and Chloroquine\/Hydroxychloroquine Affecting the New SARS-CoV-2","volume":"131","author":"Uzunova","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2008043","article-title":"A Trial of Lopinavir\u2013Ritonavir in Adults Hospitalized With Severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"New Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2020.04.001","article-title":"Efficacy and Safety of Lopinavir\/Ritonavir or Arbidol in Adult Patients With Mild\/Moderate COVID-19: An Exploratory Randomized Controlled","volume":"1","author":"Li","year":"2020","journal-title":"Trial Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative Therapeutic Efficacy of Remdesivir and Combination Lopinavir, Ritonavir, and Interferon Beta Against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat Commun"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple Combination of Interferon Beta-1b, Lopinavir\u2013Ritonavir, and Ribavirin in the Treatment of Patients Admitted to Hospital With COVID-19: An Open-Label, Randomised, Phase 2 Trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.87a.ccc030","article-title":"Antivirals for COVID-19","author":"Srinivas","year":"2020","journal-title":"Cleveland Clin J Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2165\/00003495-200363080-00004","article-title":"Lopinavir\/ritonavir: A Review of Its Use in the Management of HIV Infection","volume":"63","author":"Cvetkovic","year":"2003","journal-title":"Drugs"},{"key":"B76","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/med.21728","article-title":"COVID-19 Drug Repurposing: A Review of Computational Screening Methods, Clinical Trials, and Protein Interaction Assays","volume":"41","author":"Wang","year":"2021","journal-title":"Med Res Rev"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of Chloroquine on Viral Infections: An Old Drug Against Today\u2019s Diseases","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.589505","article-title":"Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics","volume":"10","author":"Gomes","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"e1009212","DOI":"10.1371\/journal.ppat.1009212","article-title":"Hydroxychloroquine-Mediated Inhibition of SARS-CoV-2 Entry is Attenuated by TMPRSS2","volume":"17","author":"Ou","year":"2021","journal-title":"PloS Pathogens"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a Potent Inhibitor of SARS Coronavirus Infection and Spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol J"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa237","article-title":"In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B82","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a Less Toxic Derivative of Chloroquine, is Effective in Inhibiting SARS-CoV-2 Infection In Vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01509-08","article-title":"Antiviral Activity of Chloroquine Against Human Coronavirus OC43 Infection in Newborn Mice","volume":"53","author":"Keyaerts","year":"2009","journal-title":"Antimicrobial Agents Chemother"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021801","article-title":"A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19","volume":"384","author":"Mitj\u00e0","year":"2021","journal-title":"New Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.22240","article-title":"Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial","volume":"324","author":"Self","year":"2020","journal-title":"JAMA - J Am Med Assoc"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational Study of Hydroxychloroquine in Hospitalized Patients With Covid-19","volume":"382","author":"Geleris","year":"2020","journal-title":"New Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.16253","article-title":"Emergency Use Authorizations During the COVID-19 Pandemic: Lessons From Hydroxychloroquine for Vaccine Authorization and Approval","volume":"324","author":"Thomson","year":"2020","journal-title":"JAMA - J Am Med Assoc"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3934\/microbiol.2020021","article-title":"Structural Basis of SARS-CoV-2 Spike Protein Priming by TMPRSS2","volume":"6","author":"Hussain","year":"2020","journal-title":"AIMS Microbiol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2772-0","article-title":"Receptor Binding and Priming of the Spike Protein of SARS-CoV-2 for Membrane Fusion","volume":"588","author":"Benton","year":"2020","journal-title":"Nature"},{"key":"B90","doi-asserted-by":"publisher","first-page":"103255","DOI":"10.1016\/j.ebiom.2021.103255","article-title":"Camostat Mesylate Inhibits SARS-CoV-2 Activation by TMPRSS2-Related Proteases and Its Metabolite GBPA Exerts Antiviral Activity","volume":"65","author":"Hoffmann","year":"2021","journal-title":"EBioMedicine"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc0405","article-title":"These Drugs Don\u2019t Target the Coronavirus\u2014They Target Us","author":"Kupferschmidt","year":"2020","journal-title":"Science"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00754-20","article-title":"Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19","volume":"64","author":"Hoffmann","year":"2020","journal-title":"Antimicrobial Agents Chemother"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13533","article-title":"Camostat Mesylate Against SARS-CoV-2 and COVID-19\u2014Rationale, Dosing and Safety","volume":"128","author":"Breining","year":"2021","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.0c00430","article-title":"Targeting Proteases for Treating COVID-19","volume":"19","author":"Luan","year":"2020","journal-title":"J Proteome Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.00215","article-title":"COVID-19: Targeting Proteases in Viral Invasion and Host Immune Response","volume":"7","author":"Seth","year":"2020","journal-title":"Front Mol Biosci"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1829082","article-title":"Targeting the Endolysosomal Host-SARS-CoV-2 Interface by Clinically Licensed Functional Inhibitors of Acid Sphingomyelinase (FIASMA) Including the Antidepressant Fluoxetine","volume":"9","author":"Schloer","year":"2020","journal-title":"Emerging Microbes Infect"},{"key":"B97","doi-asserted-by":"publisher","first-page":"5890","DOI":"10.1038\/s41598-021-85049-0","article-title":"The Serotonin Reuptake Inhibitor Fluoxetine Inhibits SARS-CoV-2 in Human Lung Tissue","volume":"11","author":"Zimniak","year":"2021","journal-title":"Sci Rep"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15418","article-title":"Drug Synergy of Combinatory Treatment With Remdesivir and the Repurposed Drugs Fluoxetine and Itraconazole Effectively Impairs SARS-CoV-2 Infection In Vitro","volume":"178","author":"Schloer","year":"2021","journal-title":"Br J Pharmacol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"111437","DOI":"10.1016\/j.biopha.2021.111437","article-title":"Fluoxetine as an Anti-Inflammatory Therapy in SARS-CoV-2 Infection","volume":"138","author":"Creeden","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"B100","doi-asserted-by":"publisher","first-page":"477","DOI":"10.12688\/f1000research.53275.1","article-title":"Fluoxetine Pharmacokinetics and Tissue Distribution Suggest a Possible Role in Reducing SARS-CoV-2 Titers [version 1; peer review: 2 approved with reservations]","volume":"10","author":"Eugene","year":"2021","journal-title":"F1000Research"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01021-4","article-title":"Association Between Antidepressant Use and Reduced Risk of Intubation or Death in Hospitalized Patients With COVID-19: Results From an Observational Study","author":"Hoertel","year":"2021","journal-title":"Mol Psychiatry"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug Repurposing","volume":"583","author":"Gordon","year":"2020","journal-title":"Nature"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26831","article-title":"Aplidin (Plitidepsin) is a Novel Anti-Myeloma Agent With Potent Anti-Resorptive Activity Mediated by Direct Effects on Osteoclasts","volume":"10","author":"Delgado-Calle","year":"2019","journal-title":"Oncotarget"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1126\/science.abg6837","article-title":"SARS-CoV-2 Dependence on Host Pathways","volume":"371","author":"Wong","year":"2021","journal-title":"Science"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf4058","article-title":"Plitidepsin has Potent Preclinical Efficacy Against SARS-CoV-2 by Targeting the Host Protein Eef1a","volume":"371","author":"White","year":"2021","journal-title":"Science"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1101\/2021.01.24.427991","article-title":"Host-Directed Therapies Against Early-Lineage SARS-CoV-2 Retain Efficacy Against B.1.1.7 Variant","author":"Reuschl","year":"2021","journal-title":"bioRxiv: Preprint Server Biol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03739-2","article-title":"Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"98","author":"Spicka","year":"2019","journal-title":"Ann Hematol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.04.008","article-title":"Development of Cellular Signaling Pathway Inhibitors as New Antivirals Against Influenza","volume":"98","author":"Planz","year":"2013","journal-title":"Antiviral Res"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/35060098","article-title":"Influenza Virus Propagation is Impaired by Inhibition of the Raf\/MEK\/ERK Signalling Cascade","volume":"3","author":"Pleschka","year":"2001","journal-title":"Nat Cell Biol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2002828117","article-title":"Dissecting the Mechanism of Signaling-Triggered Nuclear Export of Newly Synthesized Influenza Virus Ribonucleoprotein Complexes","volume":"117","author":"Schreiber","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B111","doi-asserted-by":"publisher","first-page":"e12955","DOI":"10.1111\/cmi.12955","article-title":"Late Activation of the Raf\/MEK\/ERK Pathway is Required for Translocation of the Respiratory Syncytial Virus F Protein to the Plasma Membrane and Efficient Viral Replication","volume":"21","author":"Preugschas","year":"2019","journal-title":"Cell Microbiol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01705-06","article-title":"Suppression of Coronavirus Replication by Inhibition of the MEK Signaling Pathway","volume":"81","author":"Cai","year":"2007","journal-title":"J Virol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104806","article-title":"Antiviral Efficacy Against Influenza Virus and Pharmacokinetic Analysis of a Novel MEK-Inhibitor, ATR-002, in Cell Culture and in the Mouse Model","volume":"178","author":"Laure","year":"2020","journal-title":"Antiviral Res"},{"key":"B114","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.antiviral.2011.05.009","article-title":"Inhibition of Influenza Virus-Induced NF-kappaB and Raf\/MEK\/ERK Activation can Reduce Both Virus Titers and Cytokine Expression Simultaneously In Vitro and In Vivo","volume":"92","author":"Pinto","year":"2011","journal-title":"Antiviral Res"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41429-021-00430-5","article-title":"The Mechanisms of Action of Ivermectin Against SARS-CoV-2: An Evidence-Based Clinical Review Article","author":"Zaidi","year":"2021","journal-title":"J\u00a0Antibiotics"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-020-00633-7","article-title":"An Aberrant STAT Pathway is Central to COVID-19","volume":"27","author":"Matsuyama","year":"2020","journal-title":"Cell Death Different"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-Approved Drug Ivermectin Inhibits the Replication of SARS-CoV-2 In Vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000001377","article-title":"Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19","volume":"28","author":"Kory","year":"2021","journal-title":"Am J Ther"},{"key":"B119","doi-asserted-by":"publisher","first-page":"e0242184","DOI":"10.1371\/journal.pone.0242184","article-title":"Lack of Efficacy of Standard Doses of Ivermectin in Severe COVID-19 Patients","volume":"15","author":"Camprub\u00ed","year":"2020","journal-title":"PloS One"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.20-0271","article-title":"Ivermectin and COVID-19: Keeping Rigor in Times of Urgency","volume":"102","author":"Chaccour","year":"2020","journal-title":"Am J Trop Med Hygiene"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.12.004","article-title":"Genetic Screens Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses","volume":"184","author":"Wang","year":"2021","journal-title":"Cell"},{"key":"B122","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cell.2020.10.030","article-title":"Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells","volume":"184","author":"Daniloski","year":"2021","journal-title":"Cell"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1101\/2021.05.06.442916","article-title":"Identification of DAXX As A Restriction Factor Of SARS-CoV-2 Through A CRISPR\/Cas9 Screen","volume":"58","author":"mac Kain","year":"2021","journal-title":"bioRxiv"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1101\/2021.04.22.440848","article-title":"Genome-Wide, Bidirectional CRISPR Screens Identify Mucins as Critical Host Factors Modulating SARS-CoV-2 Infection","author":"Biering","year":"2021","journal-title":"bioRxiv"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-021-00805-2","article-title":"Genome-Wide CRISPR Screening Identifies TMEM106B as a Proviral Host Factor for SARS-CoV-2","volume":"53","author":"Baggen","year":"2021","journal-title":"Nat Genet"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and Distinct Functions of Type I and Type III Interferons","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12010","article-title":"IFN-\u03b1 Subtypes: Distinct Biological Activities in Anti-Viral Therapy","volume":"168","author":"Gibbert","year":"2013","journal-title":"Br J Pharmacol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01410-20","article-title":"Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV","volume":"94","author":"Lokugamage","year":"2020","journal-title":"J Virol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104811","article-title":"Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection","volume":"179","author":"Mantlo","year":"2020","journal-title":"Antiviral Res"},{"key":"B130","doi-asserted-by":"publisher","first-page":"107329","DOI":"10.1016\/j.intimp.2020.107329","article-title":"Combination Therapy of Ifn\u03b21 With Lopinavir\u2013Ritonavir, Increases Oxygenation, Survival and Discharging of Sever COVID-19 Infected Inpatients","volume":"92","author":"Baghaei","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"106903","DOI":"10.1016\/j.intimp.2020.106903","article-title":"Interferon \u03b2-1b in Treatment of Severe COVID-19: A Randomized Clinical Trial","volume":"88","author":"Rahmani","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01061-20","article-title":"A Randomized Clinical Trial of the Efficacy and Safety of Interferon \u03b2-1a in Treatment of Severe COVID-19","volume":"64","author":"Davoudi-Monfared","year":"2020","journal-title":"Antimicrobial Agents Chemother"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01061","article-title":"Interferon-\u03b12b Treatment for COVID-19","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Immunol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2213-2600(20)30511-7","article-title":"Safety and Efficacy of Inhaled Nebulised Interferon Beta-1a (SNG001) for Treatment of SARS-CoV-2 Infection: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial","volume":"9","author":"Monk","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.07.005","article-title":"Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated With Favorable Clinical Responses in COVID-19 Patients","volume":"28","author":"Wang","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.15.20084293","article-title":"Clinical Evaluation of IFN Beta1b in COVID-19 Pneumonia: A Retrospective Study","author":"Est\u00e9banez","year":"2020","journal-title":"bioRxiv"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1101\/2021.05.20.444757","article-title":"Differential Interferon-\u03b1 Subtype Immune Signatures Suppress SARS-CoV-2 Infection","author":"Schuhenn","year":"2021","journal-title":"bioRxiv"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.20.436257","article-title":"Interferon Resistance of Emerging SARS-CoV-2 Variants","author":"Guo","year":"2021","journal-title":"bioRxiv"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00985-20","article-title":"Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures","volume":"94","author":"Vanderheiden","year":"2020","journal-title":"J Virol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2708-8","article-title":"A Mouse-Adapted Model of SARS-CoV-2 to Test COVID-19 Countermeasures","volume":"586","author":"Dinnon","year":"2020","journal-title":"Nature"},{"key":"B141","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.21203\/rs.3.rs-110659\/v1","article-title":"Peginterferon Lambda-1a for Treatment of Outpatients With Uncomplicated COVID-19: A Randomized Placebo-Controlled Trial","volume":"12","author":"Jagannathan","year":"2021","journal-title":"Nat Commun"},{"key":"B142","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S2213-2600(20)30566-X","article-title":"Peginterferon Lambda for the Treatment of Outpatients With COVID-19: A Phase 2, Placebo-Controlled Randomised Trial","volume":"9","author":"Feld","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2019.01.004","article-title":"Trefoil Factor Family: Unresolved Questions and Clinical Perspectives","volume":"44","author":"Braga Emidio","year":"2019","journal-title":"Trends Biochem Sci"},{"key":"B144","doi-asserted-by":"publisher","first-page":"100547","DOI":"10.1016\/j.eclinm.2020.100547","article-title":"An Open-Label, Randomized Trial of the Combination of IFN-\u03ba Plus TFF2 With Standard Care in the Treatment of Patients With Moderate COVID-19","volume":"27","author":"Fu","year":"2020","journal-title":"EClinicalMedicine"},{"key":"B145","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/07853890.2021.1890329","article-title":"Effect of a Genetically Engineered Interferon-Alpha Versus Traditional Interferon-Alpha in the Treatment of Moderate-to-Severe COVID-19: A Randomised Clinical Trial","volume":"53","author":"Li","year":"2021","journal-title":"Ann Med"},{"key":"B146","doi-asserted-by":"crossref","DOI":"10.1177\/135965350400900618","article-title":"Increased Sensitivity of SARS-Coronavirus to a Combination of Human Type I and Type II Interferons","volume":"9","author":"Scagnolari","year":"2004","journal-title":"Antiviral Ther"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2004.08.011","article-title":"Interferon-Beta and Interferon-Gamma Synergistically Inhibit the Replication of Severe Acute Respiratory Syndrome-Associated Coronavirus (SARS-CoV)","volume":"329","author":"Sainz","year":"2004","journal-title":"Virology"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-33012-9_89","article-title":"Synergistic Inhibition of SARS-Coronavirus Replication by Type I and Type II IFN","volume":"581","author":"Mossel","year":"2006","journal-title":"Adv Exp Med Biol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"e8729","DOI":"10.1371\/journal.pone.0008729","article-title":"Dynamic Innate Immune Responses of Human Bronchial Epithelial Cells to Severe Acute Respiratory Syndrome-Associated Coronavirus Infection","volume":"5","author":"Yoshikawa","year":"2010","journal-title":"PloS One"},{"key":"B150","unstructured":"Esquivel-MoyneloII Vazquez-BlonquistDD CervantesCL Campa-LegraII VizcainoTM Lucila Muzio-GonzalezVV Title: Effect of Combination of Interferon Alpha-2b and Interferon-Gamma or Interferon Alpha-2b Alone for Elimination of SARS-CoV-2 Viral RNA. Preliminary Results of a Randomized Controlled Clinical Trial"},{"key":"B151","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.antiviral.2010.11.007","article-title":"Single-Dose Intranasal Administration With Mdef201 (Adenovirus Vectored Mouse Interferon-Alpha) Confers Protection From Mortality in a Lethal SARS-CoV BALB\/c Mouse Model","volume":"89","author":"Kumaki","year":"2011","journal-title":"Antiviral Res"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.2174\/1568026621666210429083050","article-title":"The Effect of Recombinant Human Interferon Alpha Nasal Drops to Prevent COVID-19 Pneumonia for Medical Staff in an Epidemic Area","volume":"21","author":"Meng","year":"2021","journal-title":"Curr Top Med Chem"},{"key":"B153","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2174\/1568026621666210429083050","article-title":"Mechanisms Involved in the Side Effects of Glucocorticoids","volume":"96","author":"Sch\u00e4cke","year":"2002","journal-title":"Pharmacol Ther"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.otc.2010.04.003","article-title":"A Comprehensive Review of the Adverse Effects of Systemic Corticosteroids","volume":"43","author":"Poetker","year":"2010","journal-title":"Otolaryngol Clin North Am"},{"key":"B155","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/d41586-020-01824-5","article-title":"Coronavirus Breakthrough: Dexamethasone is First Drug Shown to Save Lives","volume":"582","author":"Ledford","year":"2020","journal-title":"Nature"},{"key":"B156","volume-title":"Chapter 39: Adrenocorticosteroids & Adrenocortical Antagonists. Basic and Clinical Pharmacology","author":"Bertram","year":"2012"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(05)70327-6","article-title":"Infectious Complications of Immunosuppressive Therapy in Patients With Rheumatic Diseases","volume":"23","author":"Segal","year":"1997","journal-title":"Rheumatic Dis Clinics North Am"},{"key":"B158","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in Hospitalized Patients with Covid-19","volume":"384","author":"Horby","year":"2020","journal-title":"N Engl J Med"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30417-5","article-title":"Dexamethasone Treatment for the Acute Respiratory Distress Syndrome: A Multicentre, Randomised Controlled Trial","volume":"8","author":"Villar","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17021","article-title":"Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial","volume":"324","author":"Tomazini","year":"2020","journal-title":"JAMA - J Am Med Assoc"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1101\/2020.11.19.20234153","article-title":"Effectiveness of Remdesivir With and Without Dexamethasone in Hospitalized Patients With COVID-19","author":"Garibaldi","year":"2020","journal-title":"medRxiv"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.05.008","article-title":"Level of IL-6 Predicts Respiratory Failure in Hospitalized Symptomatic COVID-19 Patients","volume":"146","author":"Herold","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.arcmed.2020.05.009","article-title":"Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19","volume":"51","author":"Saha","year":"2020","journal-title":"Arch Med Res"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S3470","article-title":"Interleukin-6 Inhibitors in the Treatment of Rheumatoid Arthritis","volume":"4","author":"Hennigan","year":"2008","journal-title":"Ther Clin Risk Manage"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205351","article-title":"Efficacy and Safety of Tocilizumab in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase 3, Randomised, Double-Blind Withdrawal Trial","volume":"74","author":"Brunner","year":"2015","journal-title":"Ann Rheumatic Dis"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of Tocilizumab in Giant-Cell Arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2011.03.023","article-title":"Anti-Interleukin-6 Receptor Antibody, Tocilizumab, for the Treatment of Autoimmune Diseases","volume":"585","author":"Tanaka","year":"2011","journal-title":"FEBS Lett"},{"key":"B168","volume-title":"Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers (TOCIBRAS)","year":"2020"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab Treatment in COVID-19: A Single Center Experience","volume":"92","author":"Luo","year":"2020","journal-title":"J Med Virol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2005615117","article-title":"Effective Treatment of Severe COVID-19 Patients With Tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2100217","article-title":"Tocilizumab in Hospitalized Patients With Severe Covid-19 Pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N Engl J Med"},{"key":"B172","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in Patients Hospitalized With Covid-19 Pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N Engl J Med"},{"key":"B173","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1001\/jamainternmed.2021.2209","article-title":"Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial","volume":"181","author":"Hermine","year":"2021","journal-title":"JAMA Internal Med"},{"key":"B174","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1001\/jamainternmed.2021.0404","article-title":"Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial","volume":"181","author":"Salvarani","year":"2021","journal-title":"JAMA Internal Med"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of Tocilizumab in Patients Hospitalized With Covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"New Engl J Med"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1126\/science.abh0459","article-title":"World\u2019s Largest COVID-19 Drug Trial Identifies Second Compound That Cuts Risk of Death","author":"Kupferschmidt","year":"2021","journal-title":"Science"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70319-5","article-title":"Siltuximab for Multicentric Castleman\u2019s Disease: A Randomised, Double-Blind, Placebo-Controlled Trial","volume":"15","author":"van Rhee","year":"2014","journal-title":"Lancet Oncol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.01.20048561","article-title":"Use of Siltuximab in Patients With COVID-19 Pneumonia Requiring Ventilatory Support","author":"Gritti","year":"2020","journal-title":"medRxiv"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.7811","article-title":"Modulation of Mitogen-Activated Protein Kinase Attenuates Sepsis-Induced Acute Lung Injury in Acute Respiratory Distress Syndrome Rats","volume":"16","author":"Fang","year":"2017","journal-title":"Mol Med Rep"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.13.1685","article-title":"Inhibition of P38 Mitogen-Activated Protein Kinase Decreases Cardiomyocyte Apoptosis and Improves Cardiac Function After Myocardial Ischemia and Reperfusion","volume":"99","author":"Ma","year":"1999","journal-title":"Circulation"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cr.7290257","article-title":"Activation and Signaling of the P38 MAP Kinase Pathway","volume":"15","author":"Zarubin","year":"2005","journal-title":"Cell Res"},{"key":"B182","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.cell.2020.06.034","article-title":"The Global Phosphorylation Landscape of SARS-CoV-2 Infection","volume":"182","author":"Bouhaddou","year":"2020","journal-title":"Cell"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03493-4","article-title":"Multilevel Proteomics Reveals Host Perturbations by SARS-CoV-2 and SARS-CoV","volume":"594","author":"Stukalov","year":"2021","journal-title":"Nature"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2020.05.007","article-title":"P38 MAPK Inhibition: A Promising Therapeutic Approach for COVID-19","volume":"144","author":"Grimes","year":"2020","journal-title":"J Mol Cell Cardiol"},{"key":"B185","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20140712","article-title":"The Molecular Regulation of Janus Kinase (JAK) Activation","volume":"462","author":"Babon","year":"2014","journal-title":"Biochem J"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1038\/nri1153","article-title":"Class II Cytokine Receptors and Their Ligands: Key Antiviral and Inflammatory Modulators","volume":"3","author":"Renauld","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as Potential Treatment for 2019-Ncov Acute Respiratory Disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"key":"B188","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of Baricitinib, Upadacitinib, and Tofacitinib Mediated Regulation of Cytokine Signaling in Human Leukocyte Subpopulations","volume":"21","author":"McInnes","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.11.007","article-title":"Baricitinib Treatment Resolves Lower-Airway Macrophage Inflammation and Neutrophil Recruitment in SARS-CoV-2-Infected Rhesus Macaques","volume":"184","author":"Hoang","year":"2021","journal-title":"Cell"},{"key":"B190","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib Plus Remdesivir for Hospitalized Adults With Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"key":"B191","unstructured":"Fact Sheet for Healthcare Providers Emergency Use Authorization (EUA) of Baricitinib [Internet]"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2018.77971","article-title":"Tofacitinib in the Treatment of Patients With Rheumatoid Arthritis: Position Statement of Experts of the Polish Society for Rheumatology","volume":"56","author":"Kucharz","year":"2018","journal-title":"Reumatologia"},{"key":"B193","doi-asserted-by":"publisher","first-page":"102039","DOI":"10.1016\/j.pupt.2021.102039","article-title":"Tofacitinib Reduces Mortality in Coronavirus Disease 2019 Tofacitinib in COVID-19","volume":"69","author":"Maslennikov","year":"2021","journal-title":"Pulmonary Pharmacol Ther"},{"key":"B194","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0891-0","article-title":"The Janus Kinase 1\/2 Inhibitor Ruxolitinib in COVID-19 With Severe Systemic Hyperinflammation","volume":"34","author":"la Ros\u00e9e","year":"2020","journal-title":"Leukemia"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial\u2217","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit Care Med"},{"key":"B197","doi-asserted-by":"publisher","first-page":"e66125","DOI":"10.7554\/eLife.66125","article-title":"An Open Label Trial of Anakinra to Prevent Respiratory Failure in Covid-19","volume":"10","author":"Kyriazopoulou","year":"2021","journal-title":"eLife"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3182982add","article-title":"Antitumor Necrosis Factor Therapy is Associated With Improved Survival in Clinical Sepsis Trials: A Meta-Analysis","volume":"41","author":"Qiu","year":"2013","journal-title":"Crit Care Med"},{"key":"B199","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12918-016-0336-6","article-title":"The Effect of Inhibition of PP1 and Tnf\u03b1 Signaling on Pathogenesis of SARS Coronavirus","volume":"10","author":"McDermott","year":"2016","journal-title":"BMC Syst Biol"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1989","article-title":"Therapeutic siRNA Silencing in Inflammatory Monocytes in Mice","volume":"29","author":"Leuschner","year":"2011","journal-title":"Nat Biotechnol"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12815","article-title":"The Immunomodulatory Function of Mesenchymal Stem Cells: Mode of Action and Pathways","volume":"1351","author":"Uccelli","year":"2015","journal-title":"Ann New York Acad Sci"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-020-02598-6","article-title":"The Lasting Misery of Coronavirus Long-Haulers","volume":"585","author":"Marshall","year":"2020","journal-title":"Nature"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12603","article-title":"Persistent Symptoms in Patients After Acute COVID-19","volume":"324","author":"Carf\u00ec","year":"2020","journal-title":"JAMA"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-215818","article-title":"Long-Covid\u2019: A Cross-Sectional Study of Persisting Symptoms, Biomarker and Imaging Abnormalities Following Hospitalisation for COVID-19","volume":"76","author":"Mandal","year":"2021","journal-title":"Thorax"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32656-8","article-title":"6-Month Consequences of COVID-19 in Patients Discharged From Hospital: A Cohort Study","volume":"397","author":"Huang","year":"2021","journal-title":"Lancet"},{"key":"B206","doi-asserted-by":"publisher","first-page":"e048391","DOI":"10.1136\/bmjopen-2020-048391","article-title":"Multiorgan Impairment in Low-Risk Individuals With Post-COVID-19 Syndrome: A Prospective, Community-Based Study","volume":"11","author":"Dennis","year":"2021","journal-title":"BMJ Open"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-020-02796-2","article-title":"Editorial. Long COVID: Let Patients Help Define Long-Lasting COVID Symptoms","volume":"586","year":"2020","journal-title":"Nature"},{"key":"B208","doi-asserted-by":"publisher","first-page":"113426","DOI":"10.1016\/j.socscimed.2020.113426","article-title":"How and Why Patients Made Long Covid","volume":"268","author":"Callard","year":"2021","journal-title":"Soc Sci Med"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4938","article-title":"NICE Guideline on Long Covid","author":"Sivan","year":"2020","journal-title":"BMJ"},{"key":"B210","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S2213-2600(21)00031-X","article-title":"NICE Guideline on Long COVID","volume":"9","author":"Venkatesan","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.3310\/themedreview_41169","author":"NIHR","year":"2020","journal-title":"Living With Covid-19. A Dynamic Review of the Evidence Around Ongoing Covid-19 Symptoms (Often Called Long Covid)"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01177-6","article-title":"Editorial. Meeting the Challenge of Long COVID","volume":"26","year":"2020","journal-title":"Nat Med"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1101\/2020.11.03.367391","article-title":"Evolution of Antibody Immunity to SARS-CoV-2","volume":"591","author":"Gaebler","year":"2021","journal-title":"Nature"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2020-0896","article-title":"Autonomic Dysfunction in \u2018Long COVID\u2019: Rationale, Physiology and Management Strategies","volume":"21","author":"Dani","year":"2021","journal-title":"Clin Med J R Coll Phys London"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100100","article-title":"Functional Autoantibodies Against G-Protein Coupled Receptors in Patients With Persistent Long-COVID-19 Symptoms","volume":"4","author":"Wallukat","year":"2021","journal-title":"J Trans Autoimmun"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.11.21253225","article-title":"Are Vaccines Safe in Patients With Long COVID? A Prospective Observational Study","author":"Arnold","year":"2021","journal-title":"medRxiv"},{"key":"B217","volume-title":"The Impact of COVID Vaccination on Symptoms of Long Covid. An International Survey of 900 People With Lived Experience","year":"2021"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1101\/2021.04.11.21255153","article-title":"Vaccination Boosts Protective Responses and Counters SARS-CoV-2-Induced Pathogenic Memory B Cells","author":"Mishra","year":"2021","journal-title":"medRxiv: Preprint Server Health Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.752227\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T21:52:12Z","timestamp":1699566732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.752227\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":218,"alternative-id":["10.3389\/fimmu.2021.752227"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.752227","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,1]]},"article-number":"752227"}}